The use of the Scleroderma Clinical Trials Consortium Damage Index in systemic sclerosis
Background. The assessment of organ damage in patients with systemic sclerosis (SSc) is challenging. The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) proposed in 2019 has not been sufficiently studied and requires testing for wider use.The aim of the study was to examine the progres...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Russo |
| Baskı/Yayın Bilgisi: |
IMA PRESS LLC
2025-03-01
|
| Seri Bilgileri: | Научно-практическая ревматология |
| Konular: | |
| Online Erişim: | https://rsp.mediar-press.net/rsp/article/view/3704 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|